Anti-DLL3 antibody drug conjugates

Patent metadata

Field	Value
Publication number	US-9867887-B1
Application number	US-201715694622-A
Country	US
Kind code	B1
Filing date	Sep 1, 2017
Priority date	Feb 24, 2012
Publication date	Jan 16, 2018
Grant date	Jan 16, 2018

Abstract

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising:
(a) an anti-DLL3 antibody, or a pharmaceutically acceptable salt thereof, wherein the anti-DLL3 antibody comprises a light chain variable region set forth as SEQ ID NO: 212 and a heavy chain variable region set forth as SEQ ID NO: 213, and wherein the anti-DLL3 antibody is conjugated to one or more cytotoxic agents; and
(b) a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 , wherein the anti-DLL3 antibody is a humanized antibody.

3. The pharmaceutical composition of claim 2 , wherein the anti-DLL3 antibody comprises a human IgG1 heavy chain constant region.

4. The pharmaceutical composition of claim 2 , wherein the anti-DLL3 antibody comprises a human kappa light chain constant region.

5. The pharmaceutical composition of claim 1 , wherein the cytotoxic agent is a pyrrolobenzodiazepine (PBD), an auristatin, a maytansinoid, a calicheamicin, or a radioisotope.

6. The pharmaceutical composition of claim 5 , wherein the cytotoxic agent is a pyrrolobenzodiazepine (PBD).

7. The pharmaceutical composition of claim 6 , wherein the anti-DLL3 antibody is conjugated to the pyrrolobenzodiazepine (PBD) via a linker.

8. The pharmaceutical composition of claim 7 , wherein the pyrrolobenzodiazepine (PBD) comprises formula AC:

wherein:
the dotted lines indicate the optional presence of a double bond, and wherein only one of the dotted lines in a given ring can be a double bond;
R 2 is selected from H, OH, ═O, ═CH 2 , CN, R, OR, ═CH—R D , ═C(R D ) 2 , O—SO 2 —R, CO 2 R, COR, and halo, where R D is selected from R, CO 2 R, COR, CHO, CO 2 H, and halo;
R 6 and R 9 are each independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 10 is the linker connected to the anti-DLL3 antibody;
Q is selected from O, S and NH;
R 11 is either H, or R or, where Q is O, SO 3 M, where M is a metal cation;
R and R′ are each independently selected from optionally substituted C 1-12 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;
X is selected from O, S, and N(H);
R 2″ , R 6″ , R 7″ , R 9″ , and X″ are as defined according to R 2 , R 6 , R 7 , R 9 , and X, respectively; and
R″ is a C 3-12 alkylene group, which comprises a chain optionally interrupted by one or more heteroatoms, one or more rings, or both one or more heteroatoms and one or more rings, wherein the optional one or more rings are optionally substituted.

9. The pharmaceutical composition of claim 8 , wherein:
R 2 is R, wherein R is a C 5-20 aryl group;
R 6 and R 9 are H;
R 7 is OR, and wherein R is a C 1 alkyl;
Q is O, and wherein R 11 is H; and/or
X and X″ are O.

10. The pharmaceutical composition of claim 9 , wherein R 2 is R, wherein R is a C 5-20 aryl group.

11. The pharmaceutical composition of claim 9 , wherein R 6 and R 9 are H.

12. The pharmaceutical composition of claim 9 , wherein R 7 is OR.

13. The pharmaceutical composition of claim 12 , wherein R is a C 1 alkyl.

14. The pharmaceutical composition of claim 9 , wherein Q is O.

15. The pharmaceutical composition of claim 14 , wherein R 11 is H.

16. The pharmaceutical composition of claim 9 , wherein X and X″ are O.

17. A pharmaceutical composition comprising:
(a) an antibody drug conjugate, or a pharmaceutically acceptable salt thereof, comprising a humanized anti-DLL3 antibody conjugated to one or more cytotoxic agents via a linker, wherein the humanized anti-DLL3 antibody comprises a light chain variable region set forth as SEQ ID NO: 212 and a heavy chain variable region set forth as SEQ ID NO: 213;
and wherein the cytotoxic agent comprises a pyrrolobenzodiazepine (PBD) comprising the formula AC:

wherein:
the dotted lines indicate the optional presence of a double bond, and wherein only one of the dotted lines in a given ring can be a double bond;
R 2 is selected from H, OH, ═O, ═CH 2 , CN, R, OR, ═CH—R D , ═C(R D ) 2 , OSO 2 R, CO 2 R, COR, and halo, where R D is selected from R, CO 2 R, COR, CHO, CO 2 H, and halo;
R 6 and R 9 are each independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 10 is the linker connected to the anti-DLL3 antibody;
Q is selected from O, S and NH;
R 11 is either H, or R or, where Q is O, SO 3 M, where M is a metal cation;
R and R′ are each independently selected from optionally substituted C 1-12 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;
X is selected from O, S, and N(H);
R 2″ , R 6″ , R 7″ , R 9″ , and X″ are as defined according to R 2 , R 6 , R 7 , R 9 , and X, respectively; and
R″ is a C 3-12 alkylene group, which comprises a chain optionally interrupted by one or more heteroatoms, one or more rings, or both one or more heteroatoms and one or more rings, wherein the optional one or more rings are optionally substituted; and
(b) a pharmaceutically acceptable carrier.

18. The pharmaceutical composition of claim 17 , wherein the antibody drug conjugate comprises the structure:

wherein:
CBA is a cell binding agent, which is the anti-DLL3 antibody;
A, L 1 , and L 2 are components of the linker;
A is a connecting group connecting L 1 to the cell binding agent (CBA);
L 1 is optionally a cleavable linker;
L 2 is a covalent bond or together with the —OC(═O)— group forms a self-immolative linker; and
wherein the linker is attached to the pyrrolobenzodiazepine (PBD) at the position of the asterisk (*).

19. The pharmaceutical composition of claim 18 , wherein L 1 comprises a cleavable linker.

20. The pharmaceutical composition of claim 19 , wherein the cleavable linker comprises a dipeptide.

21. The pharmaceutical composition of claim 20 , wherein the dipeptide is Phe-Lys, Val-Ala, Val-Lys, Ala-Lys, Val-Cit, Phe-Cit, Leu-Cit, Ile-Cit, Phe-Arg, or Trp-Cit.

22. The pharmaceutical composition of claim 21 , wherein the dipeptide is Val-Ala.

23. The pharmaceutical composition of claim 17 , wherein R 2 is R, wherein R is a C 5-20 aryl group.

24. The pharmaceutical composition of claim 17 , wherein R 6 and R 9 are H.

25. The pharmaceutical composition of claim 17 , wherein R 7 is OR.

26. The pharmaceutical composition of claim 25 , wherein R is a C 1 alkyl.

27. The pharmaceutical compositi

Assignees

• Abbvie Stemcentrx Llc

Inventors

• Stull Robert A
• Saunders Laura
• Dylla Scott J
• Foord Orit
• Liu David
• Torgov Michael
• Shao Hui

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/5752

  of the lungs · CPC title

• C07K2317/35

  Valency · CPC title